Who
Eric Benevich
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Neurocrine Biosciences; Director, aTyr Pharma.
In numbers
- Trades disclosed
- 180
- Buys
- 0
- Sells
- 46
- Bought
- $0
- Sold
- $47.6M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Jun 2015
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —6,275 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $529K3,386 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —6,275 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $529K3,386 at $156.22 | filing |
| 9 Sep 2026filed 10 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $138K3,194 at $43.24 | filing |
| 9 Sep 2026filed 10 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $333K2,154 at $154.61 | filing |
| 9 Sep 2026filed 10 Sep 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,194 at $0.00 | filing |
| 9 Sep 2026filed 10 Sep 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,194 at $0.00 | filing |
| 9 Sep 2026filed 10 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $138K3,194 at $43.24 | filing |
| 9 Sep 2026filed 10 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $333K2,154 at $154.61 | filing |
| 11 May 2026filed 13 May 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,961 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,083 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —36,287 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,365 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —1,961 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,961 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,083 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —36,287 at $0.00 | filing |
News
Where Will Neurocrine Biosciences Be in 5 Years?NBIX · fool.com · 25 Oct 2026Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi SyndromeNBIX · prnewswire.com · 22 Oct 2026Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal HyperplasiaNBIX · prnewswire.com · 16 Oct 2026
0 headlines in the last 90 days name Eric Benevich; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.